Hetrombopag Olamine
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Idiopathic Thrombocytopenic Purpura
Conditions
Chronic Idiopathic Thrombocytopenic Purpura
Trial Timeline
Aug 1, 2015 → —
NCT ID
NCT02614846About Hetrombopag Olamine
Hetrombopag Olamine is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Chronic Idiopathic Thrombocytopenic Purpura. The current trial status is unknown. This product is registered under clinical trial identifier NCT02614846. Target conditions include Chronic Idiopathic Thrombocytopenic Purpura.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05944211 | Phase 2 | Recruiting |
| NCT03977805 | Phase 1 | Completed |
| NCT03603132 | Phase 1 | Completed |
| NCT03557099 | Phase 1/2 | Completed |
| NCT02614846 | Phase 1 | UNKNOWN |
| NCT02403440 | Phase 1 | UNKNOWN |
| NCT02409394 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Idiopathic Thrombocytopenic Purpura
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |